Clinical Trial VICCDERM1059
Title
Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma
Principal Investigator(s)
Details
- Protocol No. VICCDERM1059
- Open Date: 06/01/2011
- Staging: Phase IV
- Age Group: Adults
- Scope: National
- Objective: To evaluate the efficacy, safety and tolerability of two initial dose levels of Targretin capsules in patients with refractory CTCL
- Disease Sites: Lymphoma
- Therapies: Chemotherapy - cytotoxic
- Drugs: Bexarotene
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: E7273-G000-401
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
